Publications of Thomas Hogan, MD

Audit of the current drug shortage situation.
Higa GM, Ghani N, Gianni M, Hogan TF.
WV Med J. 2013;109(5):18-20.

Survival disparities in bladder, kidney, and prostate cancer in Asian-Indian & Pakistani immigrants to the United States as compared to other US ethnic groups: a Surveillance, Epidemiology and End Results (SEER) 2011 public use database study.
Hossain A, Hogan TF, Rahman R, Hobbs GR.
Cancer and Clinical Oncology. 2013;2(1):103-114.

Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
Hogan TF, Jing JY, Williams HJ, Altaha R, Xiaobing L, Qi H.
J Oncol Pharm Pract. 2009;15(2):111-117.

Cisplatin, gemcitabine and paclitaxel triplet chemotherapy in 50 patients with advanced or metastatic urothelial cancer.
Hogan TF, Lamm DL, Schuun GB, Hernadez JL, Kandzari SJ.
WV Med J. 2006;102(2):12-15.

Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer.
Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Jr., Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL.
J Clin Oncol. 2006;24(7):1079-1089.

Integrative tumor board: Transitional Cell carcinoma of the bladder.
Lamm DL, Hogan TF.
Integr Cancer Ther. 2005;4(1):48-64.

A pathologist's perspective on bone marrow aspiration and biopsy: I. Performing a bone marrow examination.
Riley RS, Hogan TF, Pavot DR, Forysthe R, Massey D, Smith E, Wright L, Jr., Ben-Ezra JM.
J Clin Lab Anal. 2004;18(2):70-90.

Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia: a case report and review of the literature.
Kurian S, Hogan TF, Bleigh OC, Dowdy YG, Merghoub T, Pandolfi PP, Wenger SL.
Cancer Genet Cytogenet. 2002;138(2):143-148.

Smoking and renal cell carcinoma.
Hogan TF, Lamm DL, Ducatman AM.
WV Med J. 2001;97(1):32-35.

Smoking and bladder cancer.
Hogan TF, Lamm DL, Riggs DR, Ducatman AM.
WV Med J. 2001;97(1):29-31.

Multi-drug resistance in chronic lymphocytic leukemia.
Friedenberg WR, Spencer SK, Musser C, Hogan TF, Rodvold KA, Rushing DA, Mazza JJ, Tewksbury DA, Marx JJ.
Leuk Lymphoma. 1999;34(1-2):171-178.

Rapid diagnosis of acute eosinophilic pneumonia (AEP) in a patient with respiratory failure using bronchoalveolar lavage (BAL) with calcofluor white (CW) staining.
Hogan TF, Riley RS, Thomas JG.
J Clin Lab Anal. 1997;11(4):202-207.

Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma.
Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, Gilchrist KW, Horton J.
Surgery. 1991;110(6):1006-1013.

Chromatographic studies of mitomycin C degradation in albumin microspheres.
Mehta RC, Hogan TF, Mardmomen S, Ma JK.
J Chromatogr. 1988;430(2):341-349.

Acute lymphoblastic leukemia with chromosomal 5;14 translocation and hypereosinophilia: case report and literature review.
Hogan TF, Koss W, Murgo AJ, Amato RS, Fontana JA, VanScoy FL.
J Clin Oncol. 1987;5(3):382-390.

CNS drug sanctuary effect. Spinal cord metastasis in transitional cell carcinoma.
Roy EP, III, Corey AL, Marano GD, Hogan TF.
WV Med J. 1987;83(9):430-431.

Kinetics of drug release from polylactic acid-hydrocortisone microcapsules.
Leelarasamee N, Howard SA, Malanga CJ, Luzzi LA, Hogan TF, Kandzari SJ, Ma JK.
J Microencapsul. 1986;3(3):171-179.

Preparation and in vitro evaluation of polylactic acid-mitomycin C microcapsules.
Tsai DC, Howard SA, Hogan TF, Malanga CJ, Kandzari SJ, Ma JK.
J Microencapsul. 1986;3(3):181-193.

Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy.
Block M, Trump D, Rose DP, Cummings KB, Hogan TF.
Cancer Treat Rep. 1984;68(5):719-722.

Prognostic significance of nuclear sizing in renal cell carcinoma.
Gilchrist KW, Hogan TF, Harberg J, Sonneland PR.
Urology. 1984;24(2):122-124.

Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma.
Kuebler JP, Hogan TF, Trump DL, Bryan GT.
Cancer Treat Rep. 1984;68(6):925-926.

A study of cyclophosphamide, adriamycin, cis-platinum, and methotrexate in advanced transitional cell carcinoma of the urinary tract.
Citrin DL, Hogan TF, Davis TE.
Cancer. 1983;51(1):1-4.

Chemohormonal therapy of metastatic prostate cancer. A pilot study.
Citrin DL, Hogan TF, Davis TE.
Cancer. 1983;52(3):410-414.

Survey of human polyomavirus (JCV, BKV) infections in 139 patients with lung cancer, breast cancer, melanoma, or lymphoma.
Hogan TF, Padgett BL, Walker DL, Borden EC, Frias Z.
Prog Clin Biol Res. 1983;105:311-324.

Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.
Borden EC, Hogan TF, Voelkel JG.
Cancer Res. 1982;42(12):4948-4953.

A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer.
Citrin DL, Hogan TF.
Cancer. 1982;50(2):201-206.

A preliminary report of mitotane therapy of advanced renal and prostate cancer.
Hogan TF, Citrin DL, Freeberg BL.
Cancer Treat Rep. 1981;65(5-6):539-540.

Human polyomavirus infections with JC virus and BK virus in renal transplant patients.
Hogan TF, Borden EC, McBain JA, Padgett BL, Walker DL.
Ann Intern Med. 1980;92(3):373-378.

Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy.
Hogan TF, Padgett BL, Walker DL, Borden EC, McBain JA.
J Clin Microbiol. 1980;11(2):178-183.


A clinical and pathological study of adrenocortical carcinoma: therapeutic implications.
Hogan TF, Gilchrist KW, Westring DW, Citrin DL.
Cancer. 1980;45(11):2880-2883.

o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC.
Cancer. 1978;42(5):2177-2181.

Renal complications during sulfonamide therapy for systemic nocardiosis.
Sooriyaarachchi GS, Hogan TF.
Wis Med J. 1978;77(2):S-8.

Gastrograffin and bowel necrosis.
Hogan TF.
Ann Intern Med. 1977;87(3):382-383.